GB0525029D0 - Receptor Antagonist - Google Patents

Receptor Antagonist

Info

Publication number
GB0525029D0
GB0525029D0 GBGB0525029.5A GB0525029A GB0525029D0 GB 0525029 D0 GB0525029 D0 GB 0525029D0 GB 0525029 A GB0525029 A GB 0525029A GB 0525029 D0 GB0525029 D0 GB 0525029D0
Authority
GB
United Kingdom
Prior art keywords
receptor antagonist
antagonist
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0525029.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Hull
Original Assignee
University of Hull
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Hull filed Critical University of Hull
Priority to GBGB0525029.5A priority Critical patent/GB0525029D0/en
Publication of GB0525029D0 publication Critical patent/GB0525029D0/en
Priority to PCT/GB2006/004304 priority patent/WO2007066068A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
GBGB0525029.5A 2005-12-08 2005-12-08 Receptor Antagonist Ceased GB0525029D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0525029.5A GB0525029D0 (en) 2005-12-08 2005-12-08 Receptor Antagonist
PCT/GB2006/004304 WO2007066068A2 (en) 2005-12-08 2006-11-17 Calcium ion channel receptor antagonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0525029.5A GB0525029D0 (en) 2005-12-08 2005-12-08 Receptor Antagonist

Publications (1)

Publication Number Publication Date
GB0525029D0 true GB0525029D0 (en) 2006-01-18

Family

ID=35735770

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0525029.5A Ceased GB0525029D0 (en) 2005-12-08 2005-12-08 Receptor Antagonist

Country Status (2)

Country Link
GB (1) GB0525029D0 (en)
WO (1) WO2007066068A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2826648C (en) 2011-02-18 2019-06-04 Endo Pharmaceuticals Inc. Aminoindane compounds and use thereof in treating pain
JP6616772B2 (en) 2013-12-16 2019-12-04 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー P2X3 and / or P2X2 / 3 compounds and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3726976A (en) * 1968-03-20 1973-04-10 J Glasser Treatment of arthritis with combinations of antihistaminic compounds and diuretics
JPH08239327A (en) * 1995-03-03 1996-09-17 Taisho Pharmaceut Co Ltd Medicine for preventing or treating chronic skeletal muscle pain
CN1047308C (en) * 1995-09-22 1999-12-15 范永昌 Oral pill for treatment of toothache
US6124282A (en) * 1997-05-22 2000-09-26 Sellers; Edward M. Drug formulations
CN1181934A (en) * 1997-10-23 1998-05-20 王书文 Analgesics suitable for tumor treatment
JP2001151677A (en) * 1999-11-26 2001-06-05 Taisho Pharmaceut Co Ltd Composition for pharyngeal use
JP2003012514A (en) * 2001-07-02 2003-01-15 Taisho Pharmaceut Co Ltd Medicament composition
US20030060422A1 (en) * 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
WO2003089007A1 (en) * 2002-04-22 2003-10-30 Adcock Ingram Intellectual Property (Proprietary) Limited Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu
CN1506088A (en) * 2002-12-05 2004-06-23 上海倍艺医药科技有限公司 Cold-treating medicine containing chlorpheniramine
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
US20050065172A1 (en) * 2003-09-23 2005-03-24 Shah Indukumar G. Solid dosage form comprising caffeine

Also Published As

Publication number Publication date
WO2007066068A2 (en) 2007-06-14
WO2007066068A3 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
TWI318206B (en) Histamine-3 receptor antagonists
GB0509275D0 (en) Synthetic receptor
EP2058304A4 (en) P2x4 receptor antagonist
ZA200803811B (en) Neuropolin antagonists
IL187424A0 (en) C5a RECEPTOR ANTAGONISTS
EP1871752A4 (en) Amidopropoxyphenyl orexin receptor antagonists
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
EP1935874A4 (en) S1p3 receptor antagonist
IL184278A0 (en) C5a RECEPTOR ANTAGONISTS
EP1874302A4 (en) Angiotensin ii receptor antagonists
IL190686A0 (en) Il-21 receptor antagonists
GB0509276D0 (en) Synthetic receptor
EP1898905A4 (en) Hydroisoindoline tachykinin receptor antagonists
ZA200903523B (en) Poly-TLR antagonist
AP2008004537A0 (en) Muscarinic receptor antagonists
GB0525029D0 (en) Receptor Antagonist
GB0414798D0 (en) Receptor
GB0516946D0 (en) Receptor
ZA200806223B (en) Muscarinic receptor antagonists
GB0413872D0 (en) Receptor
GB0522484D0 (en) Receptor
GB0510253D0 (en) Receptor
GB0522394D0 (en) Receptor
GB0522077D0 (en) Receptor
GB0508681D0 (en) Antagonist

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)